Active vitamin D is cardioprotective in experimental uraemia but not in children with CKD Stages 3-5

Anne Schön,Maren Leifheit-Nestler,Jennifer Deppe,Dagmar-Christiane Fischer,Aysun K Bayazit,Lukasz Obrycki,Nur Canpolat,Ipek Kaplan Bulut,Karolis Azukaitis,Alev Yilmaz,Sevgi Mir,Fatos Yalcinkaya,Oguz Soylemezoglu,Anette Melk,Gabriele I Stangl,Rouven Behnisch,Rukshana Shroff,Justine Bacchetta,Uwe Querfeld,Franz Schaefer,Dieter Haffner,4C and Study Consortium and the ESPN CKD-MBD Working Group

DOI: https://doi.org/10.1093/ndt/gfaa227

2021-02-20

Abstract:Background: Uraemic cardiac remodelling is associated with vitamin D and Klotho deficiency, elevated fibroblast growth factor 23 (FGF23) and activation of the renin-angiotensin system (RAS). The cardioprotective properties of active vitamin D analogues in this setting are unclear. Methods: In rats with 5/6 nephrectomy (5/6Nx) treated with calcitriol, the cardiac phenotype and local RAS activation were investigated compared with controls. A nested case-control study was performed within the Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study, including children with chronic kidney disease (CKD) Stages 3-5 [estimated glomerular filtration rate (eGFR) 25 mL/min/1.73 m2] treated with and without active vitamin D. Echocardiograms, plasma FGF23 and soluble Klotho (sKlotho) were assessed at baseline and after 9 months. Results: In rats with 5/6Nx, left ventricular (LV) hypertrophy, LV fibrosis and upregulated cardiac RAS were dose-dependently attenuated by calcitriol. Calcitriol further stimulated FGF23 synthesis in bone but not in the heart, and normalized suppressed renal Klotho expression. In the 4C study cohort, treatment over a mean period of 9 months with active vitamin D was associated with increased FGF23 and phosphate and decreased sKlotho and eGFR compared with vitamin D naïve controls, whereas LV mass index did not differ between groups. Conclusions: Active vitamin D ameliorates cardiac remodelling and normalizes renal Klotho expression in 5/6Nx rats but does not improve the cardiac phenotype in children with CKD Stages 3-5. This discrepancy may be due to further enhancement of circulating FGF23 and faster progression of CKD associated with reduced sKlotho and higher serum phosphate in vitamin D-treated patients.